Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil citrate for oligohydramnios
IRCT20220903055868N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of sildenafil in Oligohydramnios (Oligo) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Amniotic fluid index. Started Oct 2022; status: completed.
02
Drugs
sildenafil
03
Conditions
Oligohydramnios (Oligo)
Beyond the preview
Go deeper on IRCT20220903055868N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220903055868N1.